Objectives To explore the effect of electromotive drug administration of mitomycin C (EMDA-MMC) using a single dose of intravesical mitomycin C (MMC) to avoid transurethral resection (TURBT) for small non-muscle-invasive bladder cancer. Material and methods All patients presenting small (<2 cm), single or multiple papillary bladder tumors were proposed to undergo a single EMDA-MMC instillation with 60 mg MMC before planning TURBT. The end point is complete disappearance of all papillary tumors at 2-4 weeks after EMDA-MMC. Results Thirty-six instillations were given to 32 patients. In general the treatment was well supported, except for two patients who had severe bladder spasms, resulting in early evacuation of the MMC. Complete response occurred in 28% (10/36 instillations). In 4 EMDA-MMCs with multiple tumors some tumors disappeared while others remained. In 61% (22/36) the tumors remained unchanged. Conclusion A single EMDA-MMC in l papillary bladder tumors <2 cm gives insufficient ablative effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17843286.2018.1440706 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metastasis development in non-muscle-invasive bladder cancer.
Nat Rev Urol
November 2024
Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA.
Non-muscle-invasive bladder cancer (NMIBC) is the most common type of bladder cancer presentation and is characterized by a varying probability of recurrence and progression. Sporadically, patients with NMIBC might also develop tumour metastases without any pathological evidence of muscle-invasive disease within the bladder, a condition known as metastatic NMIBC. In the published literature, this phenomenon is limited to several case reports and small reviews, with few data regarding the possible aetiologies.
View Article and Find Full Text PDFNo pan-India-specific guidelines exist for the management of urological cancers. Although western guidelines are useful for informing management strategies, they do not account for the nuances of management in the Indian context. A modified Delphi method was used to provide a framework for the systematic development of India-centric guidelines for the management of three uro-oncology disease states: small renal masses, non-muscle invasive bladder cancer and high-risk/locally advanced prostate cancer.
View Article and Find Full Text PDFPrecise grading of non-muscle invasive bladder cancer with multi-scale pyramidal CNN.
Sci Rep
October 2024
Department of Bioengineering, University of Louisville, Louisville, KY, USA.
The grading of non-muscle invasive bladder cancer (NMIBC) continues to face challenges due to subjective interpretations, which affect the assessment of its severity. To address this challenge, we are developing an innovative artificial intelligence (AI) system aimed at objectively grading NMIBC. This system uses a novel convolutional neural network (CNN) architecture called the multi-scale pyramidal pretrained CNN to analyze both local and global pathology markers extracted from digital pathology images.
View Article and Find Full Text PDFIntra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non-muscle-invasive bladder cancer.
Urol Oncol
December 2024
Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. Electronic address:
Article Synopsis
- Up to 45% of high-risk non-muscle-invasive bladder cancer (NMIBC) patients may not benefit from traditional intravesical treatment, leading researchers to explore the feasibility and safety of combining it with intra-arterial chemotherapy (IAC).
- A study collected data from 143 patients diagnosed with high-risk NMIBC, dividing them into three treatment groups: one receiving only Bacillus Calmette-Guerin (BCG), another receiving BCG plus IAC, and a third receiving intravesical chemotherapy (IVC) plus IAC, with both IAC groups receiving additional courses of IAC.
- Results showed that the BCG+IAC group had significantly better recurrence and progression-free survival compared to the
Potential utility of ADNP in circulating tumor cells as biomarker for prognostics in non-muscle-invasive bladder cancer.
Sci Rep
August 2024
Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/ Hunan Cancer Hospital, Changsha, China.
Article Synopsis
- * A total of 74 bladder cancer patients and 22 non-cancer controls were tested, with results showing that higher baseline ADNP mRNA in CTCs correlated with a sensitivity of 83.33% and specificity of 73.58% for predicting tumor recurrence.
- * Despite promising findings, the study acknowledges its limitation due to a small sample size, while also highlighting the effectiveness of the detection method used for monitoring ADNP mRNA levels in
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!